Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 24;5(1):zpae085.
doi: 10.1093/sleepadvances/zpae085. eCollection 2024.

Epidemiology, patient characteristics, and treatment patterns of patients with narcolepsy in Sweden: a non-interventional study using secondary data

Anna Giertz  1 , Johan Mesterton  1   2 , Tanja Jakobsson  3 , Stephen Crawford  4 , Somraj Ghosh  4 , Anne-Marie Landtblom  5   6
Affiliations

Epidemiology, patient characteristics, and treatment patterns of patients with narcolepsy in Sweden: a non-interventional study using secondary data

Anna Giertz et al. Sleep Adv. .

Abstract

Study objectives: To estimate the prevalence and incidence and evaluate the treatment patterns of patients diagnosed with narcolepsy in specialist care in Sweden.

Methods: This non-interventional retrospective longitudinal study used Swedish register data from 2010 to 2020 and included patients diagnosed with narcolepsy (either type 1 or type 2), recorded in specialist outpatient and inpatient care from January 2015 to December 2019. All patients received an index date corresponding to the date of the first narcolepsy diagnosis.

Results: The prevalence and incidence of narcolepsy were 14.7/100 000 and 0.9/100 000 individuals, respectively, with a greater proportion of females than males. The study included 1846 prevalent narcolepsy patients of either type, of which 466 were incident. The majority of prevalent patients (87.9%) were prescribed narcolepsy-related treatment at index with stimulants being the most common treatment. Both in the years before and after index, the most used medication by prevalent patients was stimulants (42.4% and 54.8%, respectively). Among incident patients, stimulants were the most common drug in the year after index (57.0%). Treatment switching following index was frequent and a large share of incident patients who started on modafinil were switched to stimulants.

Conclusions: The prevalence of narcolepsy was lower than previously reported and was higher in females than in males; incidence was comparable throughout the study period. At index, not all patients used narcolepsy-related medications, potentially indicating a hesitance towards treatment and/or a need for faster initiation of treatment following index. Many patients were switched from the treatment they first initiated after diagnosis, which might be due to a lack of efficacy and/or unacceptable side effects.

Keywords: Sweden; incidence; narcolepsy; prevalence; treatment patterns.

PubMed Disclaimer

Figures

Graphical Abstract
Graphical Abstract
Figure 1.
Figure 1.
Schematic overview of the study period.
Figure 2.
Figure 2.
Prevalence of narcolepsy in specialist care in Sweden between 2015 and 2020.
Figure 3.
Figure 3.
Incidence of narcolepsy in specialist care in Sweden between 2015 and 2020.
Figure 4.
Figure 4.
Treatment switch pattern in prevalent patients.
Figure 5.
Figure 5.
Treatment switch pattern in incident patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Bhattarai J, Sumerall S. Current and future treatment options for narcolepsy: a review. Sleep Sci. 2017;10(1):19–27. doi: https://doi.org/10.5935/1984-0063.20170004 - DOI - PMC - PubMed
    1. Chavda V, Chaurasia B, Umana GE, Tomasi SO, Lu B, Montemurro N. Narcolepsy-a neuropathological obscure sleep disorder: a narrative review of current literature. Brain Sci. 2022;12(11):1473. doi: https://doi.org/10.3390/brainsci12111473 - DOI - PMC - PubMed
    1. AASM. The AASM International Classification of Sleep Disorders – Third Edition, Text Revision (ICSD-3-TR). https://aasm.org/clinical-resources/international-classification-sleep-d.... 2023. Accessed June 20, 2023.
    1. Szabo ST, Thorpy MJ, Mayer G, Peever JH, Kilduff TS. Neurobiological and immunogenetic aspects of narcolepsy: implications for pharmacotherapy. Sleep Med Rev. 2019;43:23–36. doi: https://doi.org/10.1016/j.smrv.2018.09.006 - DOI - PMC - PubMed
    1. Scheer D, Schwartz SW, Parr M, Zgibor J, Sanchez-Anguiano A, Rajaram L. Prevalence and incidence of narcolepsy in a US health care claims database, 2008-2010. Sleep. 2019;42(7). doi: https://doi.org/10.1093/sleep/zsz091 - DOI - PubMed

LinkOut - more resources